Evidence map›Paper›PMID 22728230›Full record

Trial reportBone2012

Sclerostin levels and bone turnover markers in adolescents with anorexia nervosa and healthy adolescent girls.

Alexander T Faje, Pouneh K Fazeli, Debra K Katzman, Karen K Miller, Anne Breggia, Clifford J Rosen, Nara Mendes, Anne Klibanski, Madhusmita Misra

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Bone, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
6.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.

  1. State of the art systematic review of bone disease in anorexia nervosa.The International journal of eating disorders · 2016
    Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Low bone mineral density in anorexia nervosa: Treatments and challenges.Clinical reviews in bone and mineral metabolism · 2019
    Article
  15. Article
  16. Review
  17. Anorexia Nervosa and Bone.Current opinion in endocrine and metabolic research · 2018
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Alexander T FajeNeuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Pouneh K Fazeli
Debra K Katzman
Karen K Miller
Anne Breggia
Clifford J Rosen
Nara Mendes
Anne Klibanski
Madhusmita Misra
Harvard University · USMaine Medical Center · USMassachusetts General Hospital · USHospital for Sick Children · CA

Funding

HARVARD CLINICAL AND TRANSLATIONAL SCIENCE CENTER (UL1)UL1RR025758 · NCRR · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2008 to 2011
$91.4M
ROLE OF DIETARY CONSTITUENTS ON GENE EXPRESSION IN INTESTINAL EPITHELIUMP30DK040561 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI MARTIN TORRIANI · 1994 to 2026
$31.6M
Interdisciplinary Study of Marrow Adiposity, Mineral Metabolism & Energy BalanceR24DK092759 · NIDDK · MAINEHEALTH · PI HOROWITZ, MARK C, MACDOUGALD, ORMOND A · 2011 to 2019
$13.0M
Effects of Anorexia Nervosa on Peak Bone MassR01DK062249 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI KLIBANSKI, ANNE · 2003 to 2015
$7.2M
The Role of PTH in the Low Bone Mass of Anorexia NervosaK23DK094820 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI FAZELI, POUNEH KHADEJEH · 2012 to 2015
$746k
NCRR NIH HHS UL1 RR025758NCRR NIH HHS UL1 RR025758-01NIDDK NIH HHS K23 DK094820NIDDK NIH HHS P30 DK040561NIDDK NIH HHS R01 DK062249NIDDK NIH HHS R24 DK092759
6 · The paper itself

Abstract

Sclerostin, product of the SOST gene, is an important determinant of bone formation and resorption. Adolescents with anorexia nervosa (AN) have low bone density and decreased levels of bone turnover markers. However, sclerostin has not been examined in AN as a potential mediator of impaired bone metabolism. Our study objectives were to (i) assess associations of sclerostin with surrogate bone turnover markers in girls with AN and controls and (ii) examine effects of transdermal estradiol on sclerostin in AN. 69 girls (44 with AN and 25 normal-weight controls) 13-18 years old were studied at baseline. 22 AN girls were randomized to transdermal estradiol (plus cyclic medroxyprogesterone) or placebo in a double-blind study for 12 months. Sclerostin correlated positively with P1NP and CTX in controls (r=0.67 and 0.53, p=0.0002 and 0.005, respectively) but not in AN despite comparable levels at baseline. Changes in sclerostin over twelve months did not differ in girls randomized to estradiol or placebo. The relationship between sclerostin and bone turnover markers is disrupted in adolescent girls with AN. Despite an increase in BMD with estradiol administration in AN, estrogen does not impact sclerostin levels in this group.

Indexed as

Bone RemodelingHealthAdaptor Proteins, Signal TransducingAdolescentAnorexia NervosaBiomarkersBody CompositionBody WeightBone DensityBone Morphogenetic ProteinsCase-Control StudiesEstradiolFemaleGenetic MarkersHormone Replacement TherapyHumansAdaptor Proteins, Signal TransducingBiomarkersBone Morphogenetic ProteinsEstradiolGenetic MarkersSOST protein, human

Identifiers

PMID22728230
PMCPMC3412913
OpenAlexW2062392055

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.